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Abstract Calbindin2skD a is implicated in cytosolic alcium trans- 
port and calcioprotection functions, principally as a mobile cal- 
cium buffer. Using immunoblotting, we have found that 36% of 
total calbindin2skDa is in the particulate fraction of rat brain. 
Particulate calbindin2skD, was located both within and outside 
organelles and required detergent for solnbilisation. Equivalent 
observations were made for calbindin3okDa, 27% of which was 
insoluble. These findings indicate that a substantial proportion of 
calbindin does not function as a mobile calcium buffer, and per- 
haps instead has a calcium signalling role through target ligands 
in the insoluble cellular fraction. 
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1. Introduction 
Calbindin28kD ~ is a high affinity calcium-binding protein be- 
longing to the calmodulin superfamily (reviewed in [1,2]), for 
which three principal roles have been proposed. First, following 
its discovery through association with vitamin D-dependent 
calcium uptake in the avian gut, calbindin28kD a has received 
considerable attention as a mediator of transcellular calcium 
transport in several tissues where it is abundantly expressed 
(e.g. kidney, dental enamel epithelium, avian intestine and egg 
shell gland) [3 6]. Second, the high abundance of calbindin28kDa 
in certain neurones conflicts with a unique function in calcium 
transport. Investigations in these cells have instead led to pur- 
ported calcioprotection (calcium buffering) roles [7 9]. A third 
possible function for calbindin28kD~, as a calmodulin-like 
transducer of the calcium signal to target proteins, i  based on 
the structural similarity between calbindinzskD~ and calmodulin, 
and recognition that the strongly conserved features of cal- 
bindin28kDa extend beyond the calcium-binding loops [10,11]. 
While potential targets for calbindinzskD a are recognised [12- 
14], the physiological relevance of such interactions remains 
unclear. CalbindinzskD . is thought to be medically important 
through its associations with normal and disturbed calcium 
homeostasis, but the current lack of a precisely defined function 
obscures understanding at the molecular level. For example, 
calbindinzskDa expression has been strongly associated with 
some neurodegenerative disorders and apoptosis, but several 
inconsistencies remain [15-20]. 
CalbindinzskDa is widely regarded as a soluble protein, resi- 
dent primarily in the cytosol [1,2]. Following subcellular frac- 
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tionation, only 4-9% of total calbindin2skDa was recovered in 
the insoluble fractions from intestine and brain, mainly associ- 
ated with the nuclear pellet [21-25]. The solubility of cal- 
bindin28kDa and its mobility through the cytosol are central to 
the putative roles as a calcium ferry or diffusible buffer [8,26]. 
Conversely, immunocytochemistry on several tissues has indi- 
cated that some calbindin28kDa is associated with subcellular 
structures including the nucleus, vesicles and cytoskeleton, but 
the proportion reported to be so localised varies considerably 
[4,23,25,27]. 
A recently discovered cognate of calbindin28kD,, termed cal- 
bindin30ko a orcalretinin, isexpressed mainly in certain eurones 
[15,16,28]. The subset of calbindin30kD~-containing eurones 
overlaps partially with that containing calbindin28kO,, suggest- 
ing that these proteins have similar but distinct functions. Con- 
cordantly, the 28 kDa and 30 kDa calbindins were found to 
have nearly equal calcium binding properties [29]. No biochem- 
ical analysis of calbindin30kD a subcellular localisation has been 
reported to our knowledge, but an association with microtu- 
bules was detected with immunocytochemistry [30]. 
Using quantitative immunoblotting, we found that 33% of 
total (SDS-soluble) calbindin28kDa was located in the particulate 
fraction of rat enamel cells, principally associated with the 
Triton-insoluble cytoskeleton [31]. To evaluate whether this 
substantial insolubility of calbindin28kD, extended to another 
enriched tissue, and to calbindin30kD~, the present study applied 
the same approach to rat brain. The results revealed a markedly 
higher proportion of insoluble calbindin than have previous 
subcellular f actionation studies, and also provided novel sup- 
port for the existence of target ligands in the insoluble cellular 
fraction. 
2. Experimental 
2.1. Extracts and subcellular fractionation 
Brains from 7-8-week-old Wistar-derived rats, anaesthetised with 
ether, were homogenised immediately or, where indicated, frozen on 
dry ice and stored at -80°C. Homogenates were p pared with a moto- 
rised tissue disperser (Tissue Tearor, from BioSpec) in 3 vols. ice-cold 
homogenisation buffer (10 mM Tris-HC1, pH 7.2, 120 mM NaC1, 5 mM 
dithiothreitol) containing protease inhibitors (0.1 mM phenymethane- 
sulfonyl fluoride, 1 mM benzamidine). Samples of homogenate were 
ultracentrifuged for 5 min at 2 x 105 Pa (= 150,000 x g) in a Beckman 
Airfuge and the resultant supernatant is referred to as soluble fraction 
or cytosol. The pellet, following one washing step of homogenising and 
resedimenting asabove, is termed the total particulate fraction. Where 
indicated, fractions enriched in nuclei, mitochondria and microsomes 
were isolated from the homogenate (200~1) by sequential centrifugation 
steps (each 5 rain t 4°C) at 1,000 x g, 15,000 x g and 150,000 x g, 
respectively. Before SDS-PAGE, all particulate fractions were routinely 
extracted with SDS denaturant (2% SDS in 10 mM Tris-HC1, pH 7.2, 
2 mM dithiothreitol) containing protease inhibitors, using bath sonica- 
tion and heating (5 min, 100°C), then clarified in a microcentrifuge 
(17,000 x g, 2 min) at room temperature. 
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2.2. Gel electrophoresis procedures 
SDS-PAGE (12.5% T, 2.7% C) with the Laemmli discontinuous 
buffer system, denaturing two-dimensional gel electrophoresis and 
45Ca-overlays were as described [31,32]. The heterogeneous mobility of 
calcium-loaded calbindins was largely overcome by including 5 mM 
EGTA in the sample buffer for SDS-PAGE, but in some experiments 
(e.g. Fig. IA and 4A) calcium-induced shifts were evident. 
Quantitative immunoblotting was done as documented fully else- 
where [31]. Briefly, immunoblots were developed with avidin-biotin- 
peroxidase (diaminobenzidine substrate) and quantitated by imaging 
densitometry (BioRad Model GS670) under linear conditions, using 
HPLC-purified calbindin (quantified by amino acid analysis) as inter- 
nal standard. Values obtained from this immunoassay were the same 
as those from calibrated 45Ca-overlays run in parallel ([31] and data not 
shown). Statistical comparison of the mean values for calbindin im- 
munoreactivity was done with Student's t-test (2-tailed, homoscedas- 
tic). 
2.3. Antibodies 
Antiserum to rat brain calbindin30kDa w s raised in a New Zealand 
White rabbit using the emulsified and immobilised immunogen presen- 
tations and administration routes described before [32]. Using native 
dot blots and denaturing immunoblots of protein standards and cere- 
bellum cytosol, the antiserum at 0.01 dilution was found to be mono- 
specific for low nanogram amounts of calbindin30kDa with reactivity 
independent of calcium. Calbindin28kD, was detected with approxi- 
mately I0-fold lower sensitivity under these conditions (Fig. 4 and data 
not shown). The calbindin30kDa immunogen was purified from juvenile 
rat cerebellum using heat treatment (65°C), size xclusion chromatog- 
raphy and anion exchange chromatography in the presence and absence 
of calcium [31]. Monospecific antiserum to rat brain calbindin28kDa w s 
similarly prepared and characterised asdescribed earlier [31]. 
3. Results 
3.1. Subcellular fractionation of rat brain calbindin28ko~ 
Quantitative immunoblot analysis of the soluble fraction 
(150,000 × g supernatant) from freshly dissected cerebellum re- 
vealed calbindin28kDa in high specific abundance (9 + 2/zg.mg 
protein-I; + S.E.M., n -- 3), consistent with data obtained using 
other immunoassays and 45Ca-overlay analysis [31,33]. How- 
ever, contrary to calbindin28kD, being a soluble protein, sub- 
stantial immunoreactivity was also detected in the SDS-solubil- 
ised particulate fraction (Fig. 1A). A further SDS extraction of 
the residual pellet yielded no additional calbindin2skDa. Den- 
sitometry indicated that, at some higher sample loadings where 
the soluble fraction gave a linear response, immunoreactivity 
of the SDS extract was non-linear leading to underestimation 
of particulate calbindin28kD .. The likelihood that the nonlinear- 
ity arose from sample overloading was supported by analysis 
of parallel gels stained with Coomassie blue. When the pellet 
was instead extracted with Triton X-100, increased amounts of 
calbindin2skDa were detected and the immunoreactivity was lin- 
ear. Subsequent treatment of the Triton-insoluble fraction with 
SDS released little additional calbindin28kO a (Fig. 1A). To- 
gether, particulate calbindin28kOa solubilised sequentially with 
Triton X-100 and SDS amounted to 36 + 2% (n = 5) of the total 
calbindin28kD a detected. 
To establish whether this behaviour was a feature of the 
cerebellum, where calbindin28kDa expression levels are excep- 
tionally high, the analyses were repeated on cerebrum. Again, 
it was found that particulate calbindin28kO, accounted for ver 
one-third (35 _+ 3%, n = 3) of the total immunoreactivity (Fig. 
1A). Equivalent results were also obtained with cerebellum and 
cerebrum samples that had been stored at -80°C.  
Subfractionation of the pellet into crude nuclear, mitochon- 
A 
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Fig. 1. Subcellular localisation of calbindin28kO a in rat brain by im- 
munoblotting. Homogenates of cerebellum (Cere) and forebrain (Fore) 
were ultracentrifuged to give the soluble (S150) and total particulate 
(P~50) fractions, or differentially centrifuged to give the crude nuclear 
(Nucl), mitochondrial (Mito) and microvesicular (Vesi) fractions, as 
described in section 2. No immunoreaction product accumulated out- 
side the regions shown, as illustrated elsewhere [31]. (A) The once- 
washed pellets were extracted with buffer (10 mM Tris-HCl, pH 7.2, 
2 mM dithiothreitol) containing 2% SDS (at 100°C) or 2% Triton X-100 
(at 4°C) as indicated. In lane 4, the Triton-insoluble residue from lane 
3 was extracted with 2% SDS. All fractions were adjusted to the original 
volume of homogenate b fore 1 pl samples were taken. (B) The pellets 
from cerebellum were extracted with SDS and sampled to give equal 
volume or equal protein loads (based on Coomassie blue-stained SDS- 
PAGE), as indicated. Cerebrum gave the same result. 
drial and microvesicular components showed that cal- 
bindin28ko a was located predominantly (93-96%, n = 2) in the 
nuclear fraction. When compared using equal protein loadings, 
calbindin28kDa was more evenly distributed among the three 
particulate fractions (Fig. 1B). To ensure that the apparent 
insolubility of calbindin28kDa did not reflect incomplete tissue 
disruption, cerebellum was subjected to three cycles of homo- 
genisation and ultracentrifugation. Analysis of immunoblots 
and parallel gels stained with Coomassie blue showed that the 
specific abundance of calbindin28kDa after three homogenisation 
steps was 90% (n = 2) compared to that after a single step (see 
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Fig. 2. Solubility analysis of particulate calbindin28kD a. Samples of total 
particulate fraction from whole brain were resuspended for 30 rain in 
ice-cold homogenisation buffer containing the following additives, then 
ultracentrifuged and the resultant soluble (Supt) and particulate (Pell) 
fractions (2/A samples) immunoblotted: lane 1 = no additive; lane 
2 = 10 mM EGTA; lane 3 = 1 M NaCI (final concentration); lane 4 = 6 
M urea; lane 5 = 2% Triton-X100. 
above), indicating that the standard homogenisation was essen- 
tially complete (data not shown). Moreover, this and another 
experiment with multiple wash steps (Fig. 2) confirmed that the 
particulate localisation did not reflect rapping of cytosol in the 
interstices of the pellet. 
3.2. Characterisation of particulate calbindineskDa 
To assess more stringently the apparent equivalence of solu- 
ble and particulate calbindin28kO a (Fig. 1A), samples were sub- 
jected to denaturing two-dimensional gel electrophoresis with 
immunodetection. No differences were detected between Tri- 
ton-solubilised and cytosolic albindin28kO,, both when analy- 
sed individually and as a mixture, indicating identity. Particu- 
late calbindinzskD a also retained the ability to bind calcium, as 
assessed by 45Ca-overlay analysis (data not shown). 
Several calcium-binding proteins, including calmodulin and 
the annexins, are known to undergo calcium-dependent i ter- 
actions with components of the particulate fraction. When 
brain pellets were extracted with the calcium chelator EGTA, 
only a minimal increase of solubilised calbindin2skoa was ob- 
tained compared with the standard buffer that contained = 10 
pM calcium (Fig. 2). While high ionic strength (1 M NaC1) also 
had little effect, 6 M urea released a significant amount (18- 
22%, n = 2) of calbindin28kDa. Together, these findings and the 
almost complete solubility in Triton X-100 (Figs. 1A and 2) 
suggested that calbindin2sko a was tightly bound to, or seques- 
tered within, Triton-labile components of the particulate frac- 
tion. 
To establish whether particulate calbindin28kDa was located 
inside or outside organelles, we tested its accessibility otrypsin. 
Without Triton X-100, only 43 + 3% (n = 3) of calbindin28kD a 
was degraded compared to digests in the presence of detergent 
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(Fig. 3), suggesting a dual localisation within and outside mem- 
brane-limited compartments. Cytosolic albindin28kDa was com- 
pletely degraded within 30 min under these conditions (data not 
shown). 
3.3. Subcellular fractionation and characterisation of 
calbindin3okDa 
We considered the possibility that the putative functional 
differences between calbindin28kDa nd calbindin3okOa might 
manifest as a differential subcellular localisation. The subcellu- 
lar fractionation pattern of calbindin30kO, in cerebellum and 
cerebrum (Fig. 4A) was found to parallel that of calbindin28kD, 
(Fig. 1A), but densitometry evealed that a significantly smaller 
proportion of calbindin30kDa (27 + 1% of the total, n = 3; 
P < 0.02) was particulate. The partitioning of calbindin30kD a 
between the crude nuclear, mitochondrial nd vesicular frac- 
tions (Fig. 4B) also mimicked that of calbindin28kDa (Fig. 1B). 
Likewise, in the other experiments described above, these two 
calcium-binding proteins showed equivalent behaviour (data 
not shown). 
4.  D iscuss ion  
This study showed that a substantial proportion of cal- 
bindinEskD a nd calbindina0ko a (36% and 27% of the total, re- 
spectively) is located in the particulate fraction of rat brain, 
conflicting with the general view that these high affinity cal- 
cium-binding proteins areessentially soluble constituents ofthe 
cytosol. Partitioning of the calbindins into the particulate frac- 
tion did not appear to result from their posttranslational mod- 
ification and was not modulated by calcium in a reversible 
'calmodulin-like' manner. Other evidence pointed to a dual 
compartmentalisation of particulate calbindins, both within 
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Fig. 3. Accessibility of particulate calbindin28kD . to trypsin. Samples of 
total particulate fraction from whole brain (prepared minus protease 
inhibitors) were suspended in 20 ,ul of 100 mM Tris-HC1, pH 8.0, 
containing 2% Triton X-100 where indicated. Following incubation at 
37°C, with and without 1/tg trypsin (closed and open symbols, respec- 
tively), the reactions were stopped at the indicated times by boiling in 
SDS-PAGE sample buffer then immunoblotted. 
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Fig. 4. Subcellular fractionation of calbindin30kD ~. Samples from the 
experiment in Fig. 1 were immunoblotted with anti-calbindin30kO .. The 
positions of calbindin30kD, (CB30) and calbindin28kD, (CB28) are indi- 
cated. 
and outside organelles, Together with similar data from rat 
enamel cells reported elsewhere [31 ], these findings suggest that 
calbindinzskD a and calbindin30kDa h ve target ligands and major 
signalling functions in the insoluble cellular fraction. Conse- 
quently, a substantial proportion of these calbindins is unlikely 
to function as mobile buffers or transporters of calcium in the 
cytosol. 
The relatively high proportion of particulate calbindin28kDa 
detected here in brain, and earlier in enamel cells [31], could 
result jointly from the detection approach we used and tissue- 
specific differences in calbindin28kDa compartmentalisation. In 
combination with SDS-PAGE, immunoblotting enabled the 
particulate fraction to be extracted harshly (i.e. by boiling in 
SDS) and the immunoquantitated species to be visualised and 
validated. Conversely, previous quantitations by radioimmu- 
noassay were done on samples extracted with nonionic deter- 
gent or without detergent [23-25]. Given the poor solubilisation 
of brain calbindin28kD, without Triton X-100 (Fig. 2), the low 
value reported previously (=5% insoluble in neostriatum [25]) 
might simply have reflected the omission of detergent from the 
extraction procedure. Concordantly, with intestine samples, 
values obtained for particulate calbindin28kD, without Triton 
X-100 were two-fold lower than in its presence [23,24]. How- 
ever, even the Triton values might be underestimates in some 
tissues ince most particulate calbindinzskD~ was Triton-insolu- 
ble in enamel cells [31]. It will be of interest o apply the im- 
munoblotting approach to other tissues and establish whether 
the insoluble behaviour observed in brain and enamel cells is 
a general phenomenon. A preliminary analysis of kidney indi- 
cated that particulate calbindin28kDa exceeded 15% of the total 
(unpublished ata). Several potential artefacts associated with 
subcellular f actionation (i.e. freeze/thawing effects, incomplete 
tissue disruption or washing of pellet) were addressed here, and 
others showed that insoluble calbindin28kDa did not result from 
vesicular entrapment in duodenum extracts [21]. The challenge 
remains to relate the in vitro findings, obtained with subcellular 
fractionation and other approaches, to the subcellular localisa- 
tion of calbindin that exists in vivo. 
Our biochemical evidence that much calbindin28ma is in olu- 
ble supports ome previous immunocytochemical data, but fur- 
ther investigations will be required to identify the target loca- 
tions within the particulate fraction and to determine the distri- 
bution of calbindin28kDa between them. A consistent finding in 
this and most earlier subcellular fractionation studies is that 
insoluble calbindinzskDa partitions mainly with the crude nu- 
clear fraction (Fig. 1B and [23-25,31]; exception is [22]). The 
partial protection of particulate calbindin2skD a from trypsin 
(Fig. 3 and [31]) indicates localisation within membrane-limited 
organelles, such as the nucleus. Several immunocytochemical 
studies have noted an intranuclear concentration of cal- 
bindin28ko, but descriptions of the relative abundance in this 
location vary widely, even differing between studies of the same 
tissue [4,23,25,27]. In recent studies of brain and intestine, the 
predominant localisation of calbindin28kOa was found to be in- 
side vesicular organelles (identified as lysosomes) associated 
with the cytoskeleton [5,27]. While such a distribution would 
be consistent with the observed near total solubility in Triton 
X-100 (Figs. 1A and 2), the accessibility to trypsin indicates that 
approximately half of the brain particulate calbindin28ko, is 
extravesicular (Fig. 3), although a contribution from leaky ves- 
icles cannot be ruled out. Together, the solubility and trypsin 
experiments (Figs. 2 and 3) imply that extravesicular cal- 
bindin28kD ~ is tightly associated, in a calcium-independent man- 
ner, with Triton-labile particulate structures. These characteris- 
tics point to the existence of high affinity target ligands for 
calbindin2skDa, perhaps associated with the outside of organelles 
or with the cytoskeletal components hat fractionate into the 
crude nuclear pellet. Given the marked differences in solubility 
(i.e. in Triton X-100 and urea) between brain calbindin28kD . 
(Fig. 2) and that from enamel cells [31], it seems likely that 
different arget ligands predominate in various tissues. Further 
investigations are warranted to identify the putative ligands and 
to elucidate the nature and function of their interaction with 
calbindin2skDa. It is noteworthy in this regard that we found 
soluble and particulate calbindin28kD, tobe indistinguishable by
two-dimensional immunoblotting, implying that interaction 
with the targets does not arise from posttranslational modifica- 
tion (e.g. phosphorylation) of calbindin28kO~,. 
Two principal functional implications arise from the ob- 
served insolubility of calbindin2skD ~. First, the novel evidence 
for target ligands, noted above, supports the idea that cal- 
bindin28kDa has important functions other than binding calcium, 
perhaps by being part of a stable protein complex. The putative 
target proteins seem to be either absent from the cytosol or 
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present in a nonbinding state, since cytosolic calbindin28kD . 
behaves as a monomer during size exclusion chromatography 
[21,31]. The evidence that the binding of calbindin28kOa is cal- 
cium independent, not being substantially reversed by EGTA 
after 30 rain (Fig. 2), precludes a classical calmodulin-like inter- 
action. However, it is pertinent hat in some cases calmodulin 
binding is not readily disrupted by EGTA [34] and that some 
calmodulin-like proteins (e.g. the B subunit ofcalcineurin) form 
tight complexes with other proteins (i.e. the catalytic subunit, 
calcineurin A) which persist in the presence of EGTA [35]. 
Hence it now seems reasonable to propose that calbindin2sko, 
could be the calcium-signalling component of a multisubunit 
protein. Second, our observation i  brain and enamel cells, that 
a major proportion of calbindin28kOa is effectively immobile in 
the insoluble fraction, is at variance with its putative roles as 
a diffusible cytosolic protein involved in calcioprotective buff- 
ering or calcium transport. While intravesicular calbindinEskDa 
could possibly be involved in calcium transcytosis through bulk 
vesicle translocation [5], the quantitative basis of this proposed 
mechanism is open to question [3]. Further work will be re- 
quired to establish whether the soluble pool of calbindin28kDa 
has a separate function, centred on calcium buffering, or in- 
stead acts as a reservoir for the proposed signalling-based insol- 
uble pool. 
Finally, the finding that calbindin30kDa behaves like cal- 
bindinzskO a during subcellular fractionation supports the notion 
that calbindin3okD, tOO has target ligands, as suggested by its 
strikingly conserved primary structure [28]. The decreased pro- 
portion of insoluble calbindin30kD a, relative to calbindinzskD ~ 
(Figs. 1A and 4A), is consistent with these cognate proteins 
having similar but nonidentical functions. 
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